Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.

Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S (2018); Gut. pii: gutjnl-2018-316023. doi: 10.1136/gutjnl-2018-316023

Institutions & Partners

By continuing to use the site, you agree to the use of cookies and our privacy policy.